Clinical Trial Update: Phase I/II Trial of Valproic Acid and Karenitecin for Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II melanoma trial evaluating valproic acid with karenitecin has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Karenitecin
• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Malignant Melanoma | Phase 1, Phase 2 | Status: TERMINATED